Overview

A Study Evaluating the Efficacy and Safety of BMS-986256 Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Status:
Not yet recruiting

Trial end date:
2024-05-02

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effectiveness, safety and tolerability of BMS-986256 in participants with active SLE.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb